Related Experiment Video

Updated: Jun 28, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Genetic modelling of the PTEN/AKT pathway in cancer research

Oliver Renner1, Carmen Blanco-Aparicio, Amancio Carnero

  • 1Experimental Therapeutics Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|October 23, 2008
PubMed

Insights

Genetically engineered mouse models are crucial for understanding cancer development and evaluating targeted therapies. These models illuminate the PTEN/AKT pathway

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Targeted cancer therapies are driven by research into molecular pathways in tumorigenesis.
  • Genetically engineered mouse models are vital for studying cancer initiation, progression, and evaluating therapeutic strategies.
  • The PTEN/AKT pathway is frequently dysregulated in human cancers and plays a key role in signal transduction.

Purpose of the Study:

  • To review key animal models used to understand the PTEN/AKT signaling network.
  • To summarize how these models contribute to comprehending tumorigenesis.
  • To highlight the role of mouse models in advancing targeted cancer therapy research.

Main Methods:

  • Utilizing genetically engineered mouse models that express oncogenes, harbor specific mutations, or have inactivated tumor suppressor genes.
  • Physiological-level investigation of molecular pathways involved in tumor initiation and progression.
  • Evaluation of molecular targeted therapies and identification of new therapeutic targets.

Main Results:

  • Genetically engineered mice have elucidated the physiological roles of PTEN/AKT pathway components.
  • These models provide insights into how pathway dysregulation contributes to cancer development.
  • Mouse models facilitate the assessment of targeted therapy efficacy.

Conclusions:

  • Genetically engineered mouse models are indispensable tools for cancer research.
  • Understanding the PTEN/AKT pathway through these models aids in developing novel targeted therapies.
  • Animal models are critical for advancing our knowledge of cancer biology and treatment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...